<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423602</url>
  </required_header>
  <id_info>
    <org_study_id>P528-00</org_study_id>
    <nct_id>NCT03423602</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of Large Hole Vascular Closure Device FIV</brief_title>
  <acronym>Frontier-IV</acronym>
  <official_title>Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivasure Medical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivasure Medical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Clinical Investigation Plan (CIP) is to:

        1. Confirm the safety and performance of the PerQseal® large hole closure system.

        2. To expand its indications of use to include common femoral arteriotomies created with 12
           to 20 F sheaths in patients undergoing endovascular procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, multi-centred, non-randomized study to investigate the
      safety and performance of the PerQseal® in 75 patients in approximately 10 European
      investigational sites.

      The study shall not be blinded prior to, during or post the procedure. All patients
      undergoing an endovascular procedure requiring an arteriotomy created by 12 to 20 F sheaths,
      via the common femoral artery will be screened against the inclusion/exclusion criteria. If
      the patient meets the requirements of the clinical investigation, they shall be invited to
      participate, provide informed consent and shall subsequently be assigned a subject number.

      All subjects shall have an immediately post procedure, ~24 hour, 1 and 3 month follow-up
      assessment. Safety data from the follow-ups will be assessed by the Data Safety Monitoring
      Committee on a continuous basis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, multi-centred, non-randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major vascular complications [Safety]</measure>
    <time_frame>up to 1 month post implantation</time_frame>
    <description>Incidence of major vascular access site complications related to the PerQseal® closure device (as defined by VARC-2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minor vascular complications [Safety]</measure>
    <time_frame>up to 1 month from implantation</time_frame>
    <description>Incidence of minor vascular access site complications directly related to the PerQseal® closure device (as defined by VARC-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study device technical success rate [Performance]</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Technical success rate for the PerQseal® closure device (percentage of subjects not requiring alternative therapy to achieve haemostasis)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Percutaneous CFA Arteriotomy Closure</condition>
  <arm_group>
    <arm_group_label>Investigational device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PerQseal® closure system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PerQseal®</intervention_name>
    <description>Large hole closure system</description>
    <arm_group_label>Investigational device</arm_group_label>
    <other_name>DP2-FA1-4 DP2-FA1-5 DP2-FA1-6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I. Over 18 years of age. ii. Subject is willing and able to provide appropriate
        study-specific informed consent, follow protocol procedures, and comply with follow-up
        visit requirements.

        iii. Clinically indicated for an endovascular procedure using a common femoral arteriotomy
        created by a 12 - 20 F sheath.

        Exclusion Criteria:

        i. Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of
        less than six months.

        ii. Evidence of systemic bacterial or cutaneous infection, including groin infection.

        iii. Known bleeding diathesis, definite or potential coagulopathy, platelet count &lt;
        100,000/μl or patients on long term anticoagulants with an INR greater than 1.2 at time of
        procedure or known type II heparin-induced thrombocytopenia.

        iv. Severe; claudication or peripheral vascular disease (e.g. Rutherford category 3 or
        greater or ABI &lt; 0.5), documented untreated iliac artery diameter stenosis &gt; 50% or
        previous bypass surgery/stent placement in the common femoral artery of ipsilateral limb.

        v. Known allergy to any of the materials used in the PerQseal®. vi. Subject has undergone a
        percutaneous procedure using a non-absorbable vascular closure device (excluding suture
        mediated) for haemostasis in the ipsilateral target leg.

        vii. Patients that have undergone a percutaneous procedure in the ipsilateral leg, within
        the previous 30 days.

        viii. Patients that have undergone a percutaneous procedure using an absorbable
        intravascular closure device for haemostasis, in the ipsilateral leg, within the previous
        90 days.

        ix. Evidence of arterial diameter stenosis &gt; 20% or anterior or circumferential
        calcification within 20 mm proximal or distal to target arteriotomy site based on
        pre-procedure CT angiography.

        x. Females who are pregnant or lactating or in fertile period not taking adequate
        contraceptives. A pregnancy test may be performed.

        xi. Patients that have a lower extremity amputation from the ipsilateral or contralateral
        limb.

        xii. Arterial access other than common femoral artery obtained for ipsilateral target leg.

        xiii. Subject has a tissue tract expected to be greater than 10 cm. xiv. Use of
        thrombolytic agents within 24 hours prior to or during the endovascular procedure which
        causes fibrinogen &lt; 100 mg/dl.

        xv. Significant blood loss/transfusion (defined as requiring transfusion of 4 or more units
        of blood products) during index procedure or within 30 days prior to index procedure.

        xvi. Activated clotting time (ACT) &gt; 350 seconds immediately prior to sheath removal or if
        ACT measurements are expected to be &gt; 350 seconds for more than 24 hours after index
        procedure.

        xvii. Target puncture site is located in a vascular graft. xviii. Target arteriotomy in the
        profunda femoris or superficial femoral artery or is in common femoral artery, but within
        10 mm proximal of the bifurcation of the Superficial Femoral /Profunda Femoris artery.

        xix. PerQseal® Introducer-sheath to ipsilateral femoral artery diameter ratio is greater
        than or equal to 1.05.

        xx. Subjects with an acute haematoma of any size, arteriovenous fistula or pseudoaneurysm
        at the target access site; or angiographic evidence of arterial laceration or dissection
        within the external iliac or femoral artery before the use of the PerQseal® closure device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Arne Schwindt</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Fraziskus Hospital, Muenster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Christoph Naber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Contilia Heart and Vascular centre, Essen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Chris Martin</last_name>
    <phone>+353 9 395 440</phone>
    <email>chris.martin@vsuremed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Charité - Universitätsmedizin</name>
      <address>
        <city>Berlin-Mitte</city>
        <state>Berlin</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Michael Laule, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Henryk Dreger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik, Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hesse</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Won-Keun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Christoph Liebetrau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Matthias Renker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hesse</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Iiona Hofmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Kolja Sievert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Laura Vaskelyte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Markus Reinartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Predrag Matić, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Contilia Heart and Vascular centre</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Christoph Naber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Alexander Wolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Thomas Schmitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Pieter Ghijselinck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Esther Vogel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Sultan Alotaibi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Ingmar Seifert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Christoph Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Regina Eder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Ioannis Tsilingiris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, Herzzentrum</name>
      <address>
        <city>Köln</city>
        <state>North Rhine-Westphalia</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof Tanja Rudolph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Kai Friedrichs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Elma Kuhn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prof Volker Rudolph, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Navid Mader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prof Thorsten Wahlers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Franziskus Hospital</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dr Arne Schwindt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Theodosios Bisdas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Eberhard Schulz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Ralph von Bardeleben, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Faculty of the University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof Dierk Scheinert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Andrej Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Daniela Branzan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Holger Staab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg Medizinische Abteilung</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Christian Freker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Tobias Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Dimitry Schewel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prof Karl-Heinz Kuck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blackrock Clinic</name>
      <address>
        <city>Blackrock</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Peter Crean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Peter Crean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous vascular closure device</keyword>
  <keyword>Large hole closure device</keyword>
  <keyword>Arteriotomy closure</keyword>
  <keyword>Vascular closure device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

